Entero Healthcare & MedPlus – High-Growth Healthcare Gems at a Discount

Two Indian healthcare companies — Entero Healthcare Solutions and Medplus Health Services — have quietly delivered exceptional profit growth, with 5-year CAGRs of 152% and 131% respectively, outpacing most frontline pharma and retail peers. Yet, both trade significantly below their all-time highs — Entero by 28% and MedPlus by 37% — creating what may be a rare valuation air pocket in an otherwise expensive market. Entero Healthcare, a top-three healthcare distributor, has scaled revenue from ₹1,350 crore (FY20) to ₹5,096 crore (FY25), driven by its nationwide compliant distribution platform for pharma manufacturers. It has slashed debt from ₹600+ crore to ₹44 crore, improving financial health. Despite strong EBITDA and profit momentum, the market remains cautious due to negative operating cash flows and integration challenges post-roll-up acquisitions. MedPlus, India’s second-largest pharmacy chain with nearly 4,930 stores, grew sales from ₹2,871 crore to ₹6,136 crore over five years. Its private label push and smart pricing strategy are boosting margins. However, regulatory suspensions and a high 60% promoter pledge have weighed on sentiment despite robust underlying profitability. Both stocks offer asymmetric upside: deeply discounted valuations combined with triple-digit earnings momentum. While risks exist — cash flow friction at Entero and governance concerns at MedPlus — successful resolution could unlock massive value. For discerning investors, these companies represent high-conviction opportunities worth monitoring closely in FY27.